ArticleFrontiers in cellular and infection microbiology2018
High-Throughput Screening for Bacterial Glycosyltransferase Inhibitors.
Article in Frontiers in cellular and infection microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Salmonella T3SS effector SseK1 arginine-glycosylates the two-component response regulator OmpR to alter bile salt resistance.Scientific reports · 2023Article
- Dual RNA-Seq ofPathogens (Basel, Switzerland) · 2023Article
- Potential therapeutic targets for combating3 Biotech · 2023Review
- Catalytic DxD motif caged in Asx-turn and Met-aromatic interaction attenuates the pathogenic glycosylation of SseK2/NleB2 effectors.Scientific reports · 2022Article
- Arginine glycosylation regulates UDP-GlcNAc biosynthesis in Salmonella enterica.Scientific reports · 2022Article
- Repurposing Avasimibe to Inhibit Bacterial Glycosyltransferases.Pathogens (Basel, Switzerland) · 2022Article
- NleB2 from enteropathogenic Escherichia coli is a novel arginine-glucose transferase effector.PLoS pathogens · 2021Article
- YM155 Inhibits NleB and SseK Arginine Glycosyltransferase Activity.Pathogens (Basel, Switzerland) · 2021Article
- Arginine glycosylation enhances methylglyoxal detoxification.Scientific reports · 2021Article
- A Salmonella type III effector, PipA, works in a different manner than the PipA family effectors GogA and GtgA.PloS one · 2021Article
- Opportunities and Challenges of Bacterial Glycosylation for the Development of Novel Antibacterial Strategies.Frontiers in microbiology · 2021Review
- Synthetic Glycobiology: Parts, Systems, and Applications.ACS synthetic biology · 2020Review
- Type III Secretion Effectors with Arginine N-Glycosyltransferase Activity.Microorganisms · 2020Review
- An intra-bacterial activity for a T3SS effector.Scientific reports · 2020Article
- Metabolic inhibitors of bacterial glycan biosynthesis.Chemical science · 2020Article
- Bacteria-Catalyzed Arginine Glycosylation in Pathogens and Host.Frontiers in cellular and infection microbiology · 2020Review
- The impact of sseK2 deletion on Salmonella enterica serovar typhimurium virulence in vivo and in vitro.BMC microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The enteropathogenic and enterohemorrhagic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.